Victory Capital Management Inc Jounce Therapeutics, Inc. Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$5.04 - $8.73 $2.45 Million - $4.24 Million	-485,173 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$6.58 - $10.66 $12.2 Million - $19.8 Million	-1,856,832 Reduced 79.28%	485,173 $3.3 Million
Q1 2021 May 04, 2021	BUY	$6.73 - $13.87 $15.8 Million - $32.5 Million	2,342,005 New	2,342,005 $24.1 Million
Q2 2020 Aug 07, 2020	SELL	$4.17 - $7.58 $12,297 - $22,353	-2,949 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$2.91 - $8.7 $17 - $52	6 Added 0.2%	2,949 $14,000
Q4 2019 Feb 04, 2020	BUY	$2.81 - $9.21 $92 - $303	33 Added 1.13%	2,943 $19,000
Q3 2019 Nov 12, 2019	BUY	$3.33 - $4.93 $9,690 - $14,346	2,910 New	2,910 $10,000
Q2 2018 Aug 02, 2018	SELL	$7.27 - $21.88 $4,434 - $13,346	-610 Closed	0 $0
Q1 2018 May 04, 2018	BUY	$13.4 - $28.4 $8,174 - $17,324	610 New	610 $14,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.